Leerink Partnrs Issues Negative Estimate for Geron Earnings

Geron Co. (NASDAQ:GERN) – Investment analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Geron in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per share of ($0.05) for the quarter, down from their previous estimate of ($0.04). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.03) EPS.

GERN has been the subject of several other research reports. B. Riley cut shares of Geron from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. HC Wainwright restated a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. Scotiabank cut shares of Geron from a “sector outperform” rating to a “sector perform” rating and cut their target price for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. Finally, Barclays restated an “overweight” rating and set a $4.00 target price (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.06.

Geron Stock Down 6.3%

Shares of NASDAQ GERN opened at $1.20 on Monday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a 52 week low of $1.17 and a 52 week high of $5.34. The firm has a 50-day moving average price of $1.47 and a 200 day moving average price of $2.69. The stock has a market capitalization of $764.30 million, a price-to-earnings ratio of -3.75 and a beta of 0.76.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $49.88 million. During the same quarter last year, the business earned ($0.07) earnings per share. The business’s revenue for the quarter was up 12927.3% compared to the same quarter last year.

Institutional Investors Weigh In On Geron

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Rovin Capital UT ADV grew its holdings in shares of Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares in the last quarter. Xponance Inc. grew its holdings in shares of Geron by 12.9% during the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,829 shares in the last quarter. KBC Group NV grew its holdings in shares of Geron by 45.1% during the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 7,592 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Geron during the fourth quarter worth about $28,000. Finally, Lazari Capital Management Inc. grew its holdings in shares of Geron by 11.7% during the fourth quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company’s stock worth $271,000 after buying an additional 8,000 shares in the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.